| Literature DB >> 35229364 |
Maren Eggers1, Peggy Jungke2, Volker Wolkinger3, Rudolf Bauer3, Uwe Kessler4, Bruno Frank4.
Abstract
Respiratory viruses pose a significant threat to global health. They initially infect the naso- and oropharyngeal regions, where they amplify, cause symptoms, and may also be transmitted to new hosts. Preventing initial infection or reducing viral loads upon infection might soothe symptoms, prevent dissemination into the lower airways, or transmission to the next individual. Several natural products have well-described direct antiviral activity or may ameliorate symptoms of respiratory infections. We thus analyzed the potential of plant-derived products to inactivate respiratory viral pathogens and determined the antiviral activity of black chokeberry (Aronia melanocarpae [Michx.] Elliott), elderberry (Sambucus nigra L.), and pomegranate (Punica granatum L.) juice, as well as green tea (Camellia sinensis [L.] Kuntze) on the infectivity of the surrogate-modified vaccinia virus Ankara, and the respiratory viruses severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza A virus (IAV), and adenovirus Type 5. Black chokeberry and pomegranate juice, and green tea reduced SARS-CoV-2 and IAV titers by ≥80% or ≥99%. This suggests that oral rinsing with these products may reduce viral loads in the oral cavity which might prevent viral transmission.Entities:
Keywords: COVID-19; black chokeberry (Aronia melanocarpae); elderberry (Sambucus nigra); oral rinses; pomegranate (Punica granatum); virus transmission
Mesh:
Substances:
Year: 2022 PMID: 35229364 PMCID: PMC9111003 DOI: 10.1002/ptr.7431
Source DB: PubMed Journal: Phytother Res ISSN: 0951-418X Impact factor: 6.388
FIGURE 1Virucidal activity of the products against MVA, IAV, SARS‐CoV‐2, and AdV5. MVA, SARS‐CoV‐2, IAV, or AdV5 were incubated with green tea, black chokeberry juice, pomegranate juice, or elderberry juice for indicated contact times before serial titration and inoculation of BHK‐21, Vero E6, MDCK, or A549 cells, respectively. Viral titers were determined by monitoring cytopathic effect and calculated as tissue culture infectious dose 50 (TCID50) according to Spearman‐Kaerber (Kärber, 1931). The lower limit of quantification (LLOQ) is defined by the limit of titration (dotted line) or cytotoxicity of the compound (#). Error bars indicate standard deviation and italics above corresponding bars the decrease of titers compared to control
Antiviral activity of natural products against MVA, IAV, SARS‐CoV‐2, and AdV5
| Virus | Contact time (min) | Control | Chokeberry | Elderberry | Pomegranate | Green tea | |
|---|---|---|---|---|---|---|---|
| MVA | 5 | Titer | 7.67 ± 0.33 | 4.50 ± 0.00 | 7.00 ± 0.45 | 6.67 ± 0.33 | 6.67 ± 0.54 |
| Log10 reduction factor | 3.17 | 0.67 | 1.00 | 1.00 | |||
| Infectivity reduction (%) | 99.93 | 78.62 | 90.00 | 90.00 | |||
| 20 | Titer | 7.67 ± 0.33 | 4.50 ± 0.60 | 6.83 ± 0.42 | 6.50 ± 0.00 | 6.00 ± 0.45 | |
| Log10 reduction factor | 3.17 | 0.84 | 1.17 | 1.67 | |||
| Infectivity reduction (%) | 99.93 | 85.55 | 93.24 | 97.86 | |||
| IAV | 5 | Titer | 6.67 ± 0.33 | 2.66 ± 0.0 | ≤2.5 ± 0.0 | ≤3.5 ± 0.0 | 3.83 ± 0.0 |
| Log10 reduction factor | 4.01 | ≥4.17 | ≥3.17 | 2.84 | |||
| Infectivity reduction (%) | 99.99 | ≥99.99 | ≥99.93 | 99.86 | |||
| 20 | Titer | 6.67 ± 0.33 | 2.63 ± 0.0 | ≤2.5 ± 0.0 | ≤2.5 ± 0.0 | ≤2.5 ± 0.0 | |
| Log10 reduction factor | 4.04 | ≥4.17 | ≥4.17 | ≥4.17 | |||
| Infectivity reduction (%) | 99.99 | ≥99.99 | ≥99.99 | ≥99.99 | |||
| SARS‐CoV‐2 | 1 | Titer | 5.13 ± 0.23 | ≤3.49 ± 0.00 | 5.13 ± 0.23 | 4.43 ± 0.23 | 4.43 ± 0.23 |
| Log10 reduction factor | ≥1.64 | 0 | 0.70 | 0.70 | |||
| Infectivity reduction (%) | ≥97.71 | 0 | 80.05 | 80.05 | |||
| 5 | Titer | 5.01 ± 0.24 | ≤3.49 ± 0 | 5.24 ± 0.16 | 4.31 ± 0.12 | 4.43 ± 0.23 | |
| Log10 reduction factor | ≥1.52 | 0 | 0.70 | 0.58 | |||
| Infectivity reduction (%) | ≥96.98 | 0 | 80.05 | 73.70 | |||
| AdV5 | 5 | Titer | 8.50 ± 0.00 | 7.33 ± 0.33 | 8.50 ± 0.47 | 8.50 ± 0.60 | 8.67 ± 0.33 |
| Log10 reduction factor | 1.17 | 0 | 0 | 0 | |||
| Infectivity reduction (%) | 93.24 | 0 | 0 | 0 |
Notes: Log10 reduction factor and antiviral activity of chokeberry, elderberry, pomegranate juice, and green tea against MVA, IAV, SARS‐CoV‐2, and AdV5 after indicated contact times.
Abbreviations: AdV5 adenovirus type 5 (adenoid 75); IAV, influenza A virus (A/H1N1/Brisbane/59/2007); MVA, modified vaccinia virus Ankara; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2 (BetaCoV/France/IDF0372/2020).
Phytochemical characterization of used products
| Product | pH | Total polyphenols | Anthocyanins | Caffeine | Ellagic acid | Punicalagin A | Punicalagin B | Total catechines |
|---|---|---|---|---|---|---|---|---|
| Green tea | 4.46 | N/D | N/D | 24 | N/D | N/D | N/D | 95 |
| Black chokeberry juice | 3.69 | 913 | 27.3 | N/D | N/D | N/D | N/D | N/D |
| Pomegranate juice | 2.99 | 347 | 3.34 | N/D | 6.27 | 1.04 | 3.12 | N/D |
| Elderberry juice | 4.13 | 778 | 182 | N/D | N/D | N/D | N/D | N/D |
Notes: Single catechine analysis: (+)‐Gallocatechin: 0.33%/2.7 mg/100 ml; (–)‐Epigallocatechin: 5.02%/35 mg/100 ml; (+)‐Catechin: 0.05%/0.4 mg/100 ml; (–)‐Epigallocatechin‐3‐O‐gallat: 7.41%/39 mg/100 ml; (–)‐Epicatechin: 1.12%/9.4 mg/100 ml; (–)‐Gallocatechin‐3‐O‐gallat: 0.07%/0.6 mg/100 ml; (–)‐Epicatechin‐3‐O‐gallat: 1.50%/8 mg/100 ml.
Analysis method Folin‐Ciocalteu (Wern, Haron, & Keng, 2016): In short: Photometric assay: substance + Folin‐Ciocalteu reagent and Na2CO3 solution measurement of absorption at 765 nm. Reference and calculation as: gallic acid.
Analysis method in analogy to Pharmacopoea Europaea Ed. 10.0 mon. 1602 Myrtilli fructus recens. In short: Photometric assay: dillution in hydrochloric—methanolic and measurement of absorption at 528 nm. Calculation as Cyanidin‐3‐O‐glucosid‐chlorid by specific absorption of 718.
Analysis according to Pharmacopoea Europaea Ed. 10.0 HPLC with Coffein CRS calculation with external standard.
Analysis according to Li, Chen, Jia, Liu, and Peng (2016) HPLC calculation via external standard and calibration curve.
Calculated as EGCG, analysis according to Pharmacopoea Europaea Ed. 10.0. HPLC with external reference mixture HRS for peak identity and (−)‐Epigallocatechin‐3‐O‐gallat CRS calculation with external standard as (−)‐Epigallocatechin‐3‐O‐gallat.